Clinical Research And EvidenceFinding

Heart failure quadruple therapy value case with low cash price estimate

April 4, 2026Gregg Fonarow MD

Gregg Fonarow argues ARNI plus beta blocker plus MRA plus SGLT2 inhibitor yields large mortality and hospitalization reductions and could extend survival by 7 to 11 years, citing a cash price estimate of 78 dollars per month.

HFrEF
ARNI+BB+MRA+SGLT2i ➡️
💊 Cost $78 per month (cash price, cost plus mail order, today)
Gregg Fonarow MD
heart failurecostimplementation

See what experts are saying right now

This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.

← Back to Healthcare